706 related articles for article (PubMed ID: 17018786)
21. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort.
Brinton LA; Richesson D; Leitzmann MF; Gierach GL; Schatzkin A; Mouw T; Hollenbeck AR; Lacey JV
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3150-60. PubMed ID: 18990757
[TBL] [Abstract][Full Text] [Related]
22. Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study.
Koskela-Niska V; Lyytinen H; Riska A; Pukkala E; Ylikorkala O
Climacteric; 2013 Feb; 16(1):48-53. PubMed ID: 22640598
[TBL] [Abstract][Full Text] [Related]
23. Menopausal hormone therapy and cancer risk: An overestimated risk?
Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
[TBL] [Abstract][Full Text] [Related]
24. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe.
Stahlberg C; Pedersen AT; Lynge E; Andersen ZJ; Keiding N; Hundrup YA; Obel EB; Ottesen B
Int J Cancer; 2004 May; 109(5):721-7. PubMed ID: 14999781
[TBL] [Abstract][Full Text] [Related]
25. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.
Chlebowski RT; Manson JE; Anderson GL; Cauley JA; Aragaki AK; Stefanick ML; Lane DS; Johnson KC; Wactawski-Wende J; Chen C; Qi L; Yasmeen S; Newcomb PA; Prentice RL
J Natl Cancer Inst; 2013 Apr; 105(8):526-35. PubMed ID: 23543779
[TBL] [Abstract][Full Text] [Related]
26. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis.
Shi LF; Wu Y; Li CY
Menopause; 2016 Apr; 23(4):417-24. PubMed ID: 26506499
[TBL] [Abstract][Full Text] [Related]
27. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.
Persson I; Yuen J; Bergkvist L; Schairer C
Int J Cancer; 1996 Jul; 67(3):327-32. PubMed ID: 8707404
[TBL] [Abstract][Full Text] [Related]
28. Estrogen-progestin replacement therapy and endometrial cancer.
Pike MC; Peters RK; Cozen W; Probst-Hensch NM; Felix JC; Wan PC; Mack TM
J Natl Cancer Inst; 1997 Aug; 89(15):1110-6. PubMed ID: 9262248
[TBL] [Abstract][Full Text] [Related]
29. Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen.
Hildebrand JS; Gapstur SM; Feigelson HS; Teras LR; Thun MJ; Patel AV
Int J Cancer; 2010 Dec; 127(12):2928-35. PubMed ID: 21351271
[TBL] [Abstract][Full Text] [Related]
30. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
[TBL] [Abstract][Full Text] [Related]
31. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.
McCullough ML; Patel AV; Patel R; Rodriguez C; Feigelson HS; Bandera EV; Gansler T; Thun MJ; Calle EE
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):73-9. PubMed ID: 18187388
[TBL] [Abstract][Full Text] [Related]
32. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.
Grodstein F; Manson JE; Stampfer MJ
J Womens Health (Larchmt); 2006; 15(1):35-44. PubMed ID: 16417416
[TBL] [Abstract][Full Text] [Related]
33. Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials.
Perez MV; Wang PJ; Larson JC; Virnig BA; Cochrane B; Curb JD; Klein L; Manson JE; Martin LW; Robinson J; Wassertheil-Smoller S; Stefanick ML
Circ Arrhythm Electrophysiol; 2012 Dec; 5(6):1108-16. PubMed ID: 23169946
[TBL] [Abstract][Full Text] [Related]
34. Unopposed estrogen therapy and the risk of invasive breast cancer.
Chen WY; Manson JE; Hankinson SE; Rosner B; Holmes MD; Willett WC; Colditz GA
Arch Intern Med; 2006 May; 166(9):1027-32. PubMed ID: 16682578
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: a randomized, double-blind, controlled trial.
Cravioto MD; Durand-Carbajal M; Jiménez-Santana L; Lara-Reyes P; Seuc AH; Sánchez-Guerrero J
Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1654-63. PubMed ID: 22127965
[TBL] [Abstract][Full Text] [Related]
36. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
37. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.
Pearce CL; Chung K; Pike MC; Wu AH
Cancer; 2009 Feb; 115(3):531-9. PubMed ID: 19127543
[TBL] [Abstract][Full Text] [Related]
38. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R
JAMA; 2000 Jan; 283(4):485-91. PubMed ID: 10659874
[TBL] [Abstract][Full Text] [Related]
39. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA
JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001
[TBL] [Abstract][Full Text] [Related]
40. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
Ross RK; Paganini-Hill A; Wan PC; Pike MC
J Natl Cancer Inst; 2000 Feb; 92(4):328-32. PubMed ID: 10675382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]